Vertex Pharmaceuticals Incorporated (LON:0QZU)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 76.73B |
| Revenue (ttm) | 8.33B |
| Net Income (ttm) | 2.66B |
| Shares Out | n/a |
| EPS (ttm) | 10.27 |
| PE Ratio | 28.90 |
| Forward PE | 20.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 532 |
| Average Volume | 669 |
| Open | 409.87 |
| Previous Close | 407.46 |
| Day's Range | 404.38 - 412.00 |
| 52-Week Range | 362.50 - 519.68 |
| Beta | 0.44 |
| RSI | 58.32 |
| Earnings Date | Nov 3, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $408.85, representing a +1.15% change from its previous close.
Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News
Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News
Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR
CNBC's “Halftime Report” team discuss their top stocks and final trades.
Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR
CNBCs Halftime Report team discuss their top stocks and final trades.
Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?
Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this h...
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-dependent compa...
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $381.87, denoting a +1.39% move from the preceding trading day.
Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership
Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...
Vertex (VRTX) Initiates Phase 2 Study for ADPKD Treatment
Vertex (VRTX) Initiates Phase 2 Study for ADPKD Treatment
Vertex (VRTX) Completes Enrollment in Key Phase 2/3 Kidney Trial
Vertex (VRTX) Completes Enrollment in Key Phase 2/3 Kidney Trial
Vertex Pharmaceuticals (VRTX) Gains FDA Breakthrough Therapy Designation
Vertex Pharmaceuticals (VRTX) Gains FDA Breakthrough Therapy Designation
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals (VRTX) Receives Analyst Upgrade and PT Adjustment | VRTX Stock News
Vertex Pharmaceuticals (VRTX) Receives Analyst Upgrade and PT Adjustment | VRTX Stock News
Vertex Announces Key Advancements Across Kidney Portfolio
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated ki...
Leerink Upgrades Vertex Pharmaceuticals (VRTX) with Strong Future Prospects
Leerink Upgrades Vertex Pharmaceuticals (VRTX) with Strong Future Prospects
Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns
Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bank of America Global Healthcare Conference 2025 September 23, 2025 3:10 AM EDT Company Participants Susie Lisa - Senior Vice President of Investor ...
Vertex Pharmaceuticals Secures Italian Reimbursement Agreement For Gene-Edited Therapy CASGEVY
(RTTNews) - Vertex Pharmaceuticals (VRTX), Thursday announced a reimbursement agreement with the Italian Medicines Agency that allows eligible transfusion-dependent beta thalassemia and severe sickle ...
Vertex Pharmaceuticals (VRTX) Secures Italian Reimbursement for Gene-Edited Therapy
Vertex Pharmaceuticals (VRTX) Secures Italian Reimbursement for Gene-Edited Therapy
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (T...
This ETF Holds Stocks Insiders Want to Own
A look at the weighted underlying holdings of the FIS Bright Portfolios Focused Equity ETF (BRIF) shows an impressive 10.8% of holdings on a weighted basis have experienced insider buying within the p...
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
Here's why you can't find a Wall Street analyst who will tell you to sell this stock.
Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceutical...